Update οn the diagnosis and management of systemic lupus erythematosus
A Fanouriakis, N Tziolos, G Bertsias… - Annals of the rheumatic …, 2021 - ard.bmj.com
Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …
Lupus nephritis
Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …
KDIGO 2021 clinical practice guideline for the management of glomerular diseases
BH Rovin, SG Adler, J Barratt, F Bridoux… - Kidney …, 2021 - kidney-international.org
Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …
2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases
LR Sammaritano, BL Bermas… - Arthritis & …, 2020 - Wiley Online Library
Objective To develop an evidence‐based guideline on contraception, assisted reproductive
technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal …
technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal …
[HTML][HTML] US medical eligibility criteria for contraceptive use, 2024
AT Nguyen - MMWR. Recommendations and Reports, 2024 - cdc.gov
Summary The 2024 US Medical Eligibility Criteria for Contraceptive Use (US MEC)
comprises recommendations for the use of specific contraceptive methods by persons who …
comprises recommendations for the use of specific contraceptive methods by persons who …
[HTML][HTML] Trial of anifrolumab in active systemic lupus erythematosus
Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
Sex hormones in acquired immunity and autoimmune disease
VR Moulton - Frontiers in immunology, 2018 - frontiersin.org
Women have stronger immune responses to infections and vaccination than men.
Paradoxically, the stronger immune response comes at a steep price, which is the high …
Paradoxically, the stronger immune response comes at a steep price, which is the high …
[HTML][HTML] EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with …
L Andreoli, GK Bertsias, N Agmon-Levin… - Annals of the …, 2017 - ard.bmj.com
Objectives Develop recommendations for women9s health issues and family planning in
systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). Methods …
systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). Methods …
Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
Background/Purpose To search for a transmissible agent involved in lupus pathogenesis,
we investigated the faecal microbiota of patients with systemic lupus erythematosus (SLE) …
we investigated the faecal microbiota of patients with systemic lupus erythematosus (SLE) …